Advertisement
Australia markets closed

  • ALL ORDS

    7,937.50
    -0.40 (-0.01%)
     

  • ASX 200

    7,683.00
    -0.50 (-0.01%)
     

  • AUD/USD

    0.6529
    +0.0029 (+0.45%)
     

  • OIL

    83.28
    +0.47 (+0.57%)
     

  • GOLD

    2,337.60
    -0.80 (-0.03%)
     

  • Bitcoin AUD

    98,114.93
    -4,013.73 (-3.93%)
     

  • CMC Crypto 200

    1,362.79
    -19.78 (-1.43%)
     

  • AUD/EUR

    0.6086
    +0.0015 (+0.25%)
     

  • AUD/NZD

    1.0956
    +0.0014 (+0.13%)
     

  • NZX 50

    11,946.43
    +143.15 (+1.21%)
     

  • NASDAQ

    17,526.80
    +55.33 (+0.32%)
     

  • FTSE

    8,101.57
    +61.19 (+0.76%)
     

  • Dow Jones

    38,460.92
    -42.77 (-0.11%)
     

  • DAX

    18,009.23
    -79.47 (-0.44%)
     

  • Hang Seng

    17,284.54
    +83.27 (+0.48%)
     

  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     

Company News For Jun 19, 2019

Zacks Equity Research

  • Shares of The Boeing Co. BA climbed 5.4% after it received a $24 billion order for its 737 MAX jet plane. This was the first order for 737 MAX since its grounding in March

  • GCP Applied Technologies Inc.’s GCP shares plunged 13.2% following news that it failed to find a buyer for the whole or a part of its business which will provide adequate value to shareholders

  • G1 Therapeutics Inc. GTHX shares surged 24.1% after the company announced that its drug Trilaciclib achieved positive trial results for treating breast-cancer

  • Shares of Parsons Corp. PSN soared 5.2% after the company posted fiscal first-quarter 2019 revenues of $904 million, up 20% year over year


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
The Boeing Company (BA) : Free Stock Analysis Report
 
GCP Applied Technologies Inc. (GCP) : Free Stock Analysis Report
 
G1 THERAPEUTICS (GTHX) : Free Stock Analysis Report
 
Parsons Corp. (PSN) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research